Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human

Blood

Volumn 121, Issue 16, 2013, Pages 3185-3194

  Lo, Yu Hsun ^a   Huang, Yu Wen ^a   Wu, Yung Hsuan ^a,b   Tsai, Chi Shan ^a   Lin, Yu Chuan ^a   Mo, Shu Ting ^a   Kuo, Wen Chih ^a   Chuang, Ya Ting ^a   Jiang, Si Tse ^c   Shih, Hsiu Ming ^d   Lai, Ming Zong ^a,b,e  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL APPLIED RESEARCH LABORATORIES   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN CONTAINING A CARD DOMAIN; ARSENIC TRIOXIDE; CASPASE; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; MITOCHONDRIAL DNA; PROCASPASE 1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN PRECURSOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; URATE; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; GROWTH INHIBITOR; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRP3 PROTEIN, HUMAN; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PML PROTEIN, HUMAN; PML PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EMBRYO; FEMALE; MACROPHAGE; MALE; MITOCHONDRIAL DNA DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; CELL CULTURE; CELL LINE; DRUG EFFECT; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; ARSENICALS; CARRIER PROTEINS; CASPASE 1; CELL LINE; CELLS, CULTURED; DNA, MITOCHONDRIAL; DOWN-REGULATION; GENE DELETION; GROWTH INHIBITORS; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; OXIDES; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84879188516     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-432104     Document Type: Article

References (44)

1. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays. 2004;26(9):963-977.
2. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007;8(12): 1006-1016.
3. Salomoni P. Stemming out of a new PML era? Cell Death Differ. 2009;16(8):1083-1092.
4. Lallemand-Breitenbach V, de Thé H. PML nuclear bodies. Cold Spring Harb Perspect Biol. 2010; 2(5):a000661.
5. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 2001;20(49):7223-7233.
6. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, de Thé H. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 2006;66(12):6192-6198.
7. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2(5):E85-E90.
8. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature. 2004;431(7005):205-211.
9. Bellodi C, Kindle K, Bernassola F, et al. A cytoplasmic PML mutant inhibits p53 function. Cell Cycle. 2006;5(22):2688-2692.
10. Bellodi C, Kindle K, Bernassola F, et al. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptoralpha. J Biol Chem. 2006;281(20):14465-14473.
11. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P. A role for cytoplasmic PML in cellular resistance to viral infection. PLoS ONE. 2008; 3(5):e2277.
12. Giorgi C, Ito K, Lin HK, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science. 2010;330(6008): 1247-1251.
13. Lamkanfi M, Dixit VM. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev. 2009;227(1): 95-105.
14. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 2010; 22(1):28-33.
15. Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol. 2010;10(10):688-698.
16. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29:707-735.
17. Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13(4): 325-332.
18. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. 2012;13(4):333-2.
19. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963):296-300.
20. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784-790.
21. Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. Annu Rev Immunol. 2010;28:321-342.
22. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787-791.
23. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell. 2002;10(2): 417-426.
24. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221-225.
25. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3): 222-230.
26. Lin DY, Lai MZ, Ann DK, Shih HM. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem. 2003;278(18): 15958-15965.
27. Yuan WC, Lee YR, Huang SF, et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011; 20(2):214-228.
28. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. PML is essential for multiple apoptotic pathways. Nat Genet. 1998; 20(3):266-272.
29. Söderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3(12):995-1000.
30. Lunardi A, Gaboli M, Giorgio M, et al. A Role for PML in Innate Immunity. Genes Cancer. 2011; 2(1):10-19.
31. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, Chang KS. Promyelocytic leukemia protein sensitizes tumor necrosis factor alphainduced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem. 2003;278(14): 12294-12304.
32. Getting SJ, Flower RJ, Parente L, et al. Molecular determinants of monosodium urate crystalinduced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins. J Pharmacol Exp Ther. 1997;283(1):123-130.
33. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-241.
34. 3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 2001;193(12):1361-1371.
35. Platanias LC. Biological responses to arsenic compounds. J Biol Chem. 2009;284(28): 18583-18587.
36. Lo YH, Wu CC, Shih HM, Lai MZ. Selective activation of NFAT by promyelocytic leukemia protein. Oncogene. 2008;27(27): 3821-3830.
37. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ, Chen JD. Sequestration and inhibition of Daxxmediated transcriptional repression by PML. Mol Cell Biol. 2000;20(5):1784-1796.
38. Geoffroy MC, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res. 2011;31(1): 145-158.
39. Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Hénin D, Dejean A. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 1995;55(7):1590-1597.
40. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 2002;21(13): 3358-3369.
41. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
42. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89-102.
43. Dinarello CA. Anti-inflammatory agents: Present and future. Cell. 2010;140(6):935-950.
44. Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood. 2006;108(13):3967-3975.